Advisory Board

Introducing ACI’s Biosimilars & Innovator Biologics Advisory Board

American Conference Institute’s Biosimilars & Innovator Biologics Advisory Board was created as a part of ACI’s ongoing effort to provide industry leading content and a world-renowned speaker faculty. The board is composed of a selection of all-in-house advisers, including senior IP/Patent counsel from the leading pharmaceutical companies in the country and in some cases the world. This ‘inner circle’ counsels ACI on the impact of litigation trends and emerging topics.

Ali I. Ahmed

Executive Vice President & Chief Commercial Officer Hercules Pharmaceuticals, Inc.

Rebecca Charnas Grant

Senior Director | Associate General Counsel Genentech

Larry Coury

Senior Vice President, Litigation and Dispute Resolution Regeneron Pharmaceuticals, Inc.

Henry Gu

SVP, Head of Intellectual Property Zentalis Pharmaceuticals

Brian McCormick

Vice President - Chief Regulatory Counsel, Head of Global Regulatory Policy Teva Pharmaceuticals

Mira A. Mulvaney

Associate VP – Assistant General Patent Counsel, IP Litigation Eli Lilly and Company

Sonia Tadjalli Oskouei

Vice President, Biosimilars and Specialty Sandoz, Inc.

Dracey Poore

Director of Biosimilars Product and Solutions Marketing Cardinal Health
 
 

Chuck Sholtz

Head of Intellectual Property Verdiva Bio

Paul Walden, Ph.D

Head of Medical Affairs PharmaEssentia

Gillian Woollett

VP, Head Regulatory Strategy and Policy Samsung Bioepis

Speaking Opportunities
Share your knowledge and expertise with your industry peers and colleagues. Gain greater industry recognition as you join our group of business leaders who have helped to shape some of America’s most important industry conferences. This is an outstanding career, business networking and information sharing opportunity.

For more information please contact:
Bobby Swartout
Senior Conference Producer